Spots Global Cancer Trial Database for refractory solid tumor
Every month we try and update this database with for refractory solid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of NK012 in Patients With Refractory Solid Tumors | NCT00542958 | Cancer | NK012 | 18 Years - | Nippon Kayaku Co., Ltd. | |
| ODSH + ICE Chemotherapy in Pediatric Solid Tumors | NCT02164097 | Recurrent Solid... Refractory Soli... Sarcoma Wilms' Tumor Neuroblastoma | ODSH | 1 Year - 21 Years | New York Medical College | |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | NCT03690869 | Relapsed Solid ... Refractory Soli... Relapsed Centra... Refractory Cent... Diffuse Intrins... High Grade Glio... | cemiplimab (mon... cemiplimab (mai... Conventional or... Re-irradiation | - 25 Years | Regeneron Pharmaceuticals | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors | NCT00110357 | Cancer Refractory Soli... | Cetuximab + Iri... Cetuximab + Iri... | 1 Year - 18 Years | Eli Lilly and Company | |
| Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors | NCT02923466 | Malignant Solid... | VSV-IFNβ-NIS VSV-IFNβ-NIS an... | 18 Years - | Vyriad, Inc. | |
| Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors | NCT03443622 | Refractory Soli... | SC-43 Oral Solu... | 20 Years - 75 Years | SupremeCure Pharma Inc. | |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 | NCT05904236 | Patients With A... | Treatment with ... | 18 Years - | IconOVir Bio | |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 | NCT05904236 | Patients With A... | Treatment with ... | 18 Years - | IconOVir Bio | |
| Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors | NCT05963386 | Refractory Soli... | 177Lu-DOTA-EB-F... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| Oxaliplatin for Children With Solid Tumors | NCT01558453 | Relapsed Solid ... Refractory Soli... | Oxaliplatin | - 21 Years | Hospital Santa Marcelina | |
| Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors | NCT03443622 | Refractory Soli... | SC-43 Oral Solu... | 20 Years - 75 Years | SupremeCure Pharma Inc. | |
| Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors | NCT05963386 | Refractory Soli... | 177Lu-DOTA-EB-F... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University | |
| VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors | NCT04796012 | Solid Tumor Rhabdomyosarcom... | Atezolizumab Vincristine Irinotecan Temozolomide | 6 Months - 18 Years | University of Texas Southwestern Medical Center | |
| A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors. | NCT00651365 | Neoplasms | JNJ-38877605 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | NCT05468359 | Refractory Soli... Hepatocellular ... Malignant Solid... Pediatric Cance... Pediatric Solid... Fibrolamellar C... | Atezolizumab Sorafenib Bevacizumab Cyclophosphamid... | - 30 Years | St. Jude Children's Research Hospital | |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | NCT03690869 | Relapsed Solid ... Refractory Soli... Relapsed Centra... Refractory Cent... Diffuse Intrins... High Grade Glio... | cemiplimab (mon... cemiplimab (mai... Conventional or... Re-irradiation | - 25 Years | Regeneron Pharmaceuticals | |
| Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression | NCT06375564 | Refractory Soli... | 177Lu-AB-3PRGD2... | 18 Years - 90 Years | The First Affiliated Hospital of Xiamen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
